Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: The first 100 patients treated in Scandinavia

Scandinavian Journal of Gastroenterology

Volumn 42, Issue 2, 2007, Pages 221-227

  Ljung, Tryggve ^a,k   Thomsen, Ole Østergaard ^b   Vatn, Morten ^c   Karlén, Per ^d   Karlsen, Lars Norman ^e   Tysk, Curt ^f   Nilsson, Stefan U ^g   Kilander, Anders ^h   Gillberg, Rolf ^h   Grip, Olof ⁱ   Lindgren, Stefan ⁱ   Befrits, Ragnar ^a   Löfberg, Robert ^a,j,l  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF OSLO   (Norway)

^d STOCKHOLM SÖDER HOSPITAL   (Sweden)

^e Rogaland Hospital   (Norway)

^f ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^g CENTRAL HOSPITAL   (Sweden)

^h SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ LUND UNIVERSITY HOSPITAL   (Sweden)

^j IBD Unit   (Sweden)

^k Otsuka Pharma Scandinavia AB   (Sweden)

^l KAROLINSKA INSTITUTE   (Sweden)

more..

Author keywords

Apheresis; Crohn's disease; Inflammatory bowel disease; Leukocytes; Ulcerative colitis

Indexed keywords

ADOLESCENT; ADULT; AGED; APHERESIS; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; ENTERITIS; FEMALE; FOLLOW UP; GRANULOCYTE; HUMAN; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; SCANDINAVIA; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTES; HUMANS; INCIDENCE; INFLAMMATORY BOWEL DISEASES; LEUKAPHERESIS; MACROPHAGES; MALE; MIDDLE AGED; MONOCYTES; PROSPECTIVE STUDIES; SCANDINAVIA; TREATMENT OUTCOME;

EID: 33846979425     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520600979369     Document Type: Article

References (36)

1. Miehsler W, Gasche C. Standard therapy of Crohn's disease. Dig Dis 2003;21:146-56.
2. Hanauer S. Medical therapy for ulcerative colitis 2004. Gastroenterology 2004;126:1582-92.
3. Targan S, Hanauer S, Deventer SV, Mayer L, Present D, Braakman T, et al. A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 1997;337:1029-35.
4. Present D, Rutgeerts P, Targan S, Hanauer S, Mayer L, Hogezand RV, et al. Infliximab for the treatment of fistula in patients with Crohn's disease. N Engl J Med 1999;340: 1398-405.
5. Hanauer S, Feagan B, Lichtenstein G,Mayer L, Schreiber S, Colombel J, et al. Maintenance infliximab for Crohn's disease: the ACCENT randomized trial. Lancet 2002;359: 1541-9.
6. Cohen R, Tsang J, Hanauer S. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol 2000;95:3469-77.
7. Ricart E, Panaccione R, Loftus E, Tremaine W, Sandborn W. Infliximab for Crohn's disease in clinical practice at the Mayo clinic: The first 100 patients. Am J Gastroenterol 2001;96:722-9.
8. Colombel J, Loftus E, Tremaine W, Egan L, Harmsen W, Zinmeister A, et al. The safety profile of infliximab in patients with Crohn's disease. Mayo clinic experience in 500 patients. Gastroenterology 2004;126:19-31.
9. Ljung T, Karlen P, Schmidt D, Hellström PM, Lapidus A, Janczewska I, et al. Infliximab in inflammatory bowel disease; clinical outcome in a population based cohort from Stockholm County. Gut 2003;53:849-53.
10. Keane J, Gershon S, Wise R, Mirabile-Levens E, Kasznica J, Schwieterman W, et al. Tuberculosis associated with infliximab, a tumor necrosis factor-α neutralizing agent. N Engl J Med 2001;345:1098-104.
11. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001;345:1098-104.
12. Brown S, Green M, Gershon S, Edwards E, Braun M. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002;46:3151-8.
13. Everitt DE. Important drug warning: Centocor Inc; 2004 December.
14. Sands B, Tremaine W, Sandborn W, Rutgeerts P, Hanauer S, Mayer L, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis. Inflamm Bowel Dis 2001;7: 83-8.
15. Probert CS, Hearing SD, Schreiber S, Kuhbacher T, Ghosh S, Arnott ID, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003;52:998-1002.
16. Järnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Grännö C, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805-11.
17. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353: 2462-76.
18. Geboes K. Histopathology of Crohn's disease and ulcerative colitis. In: Satsangi J, Sutherland LR, editors. Inflammatory bowel diseases, 1st ed. Philadelphia: Elsevier Limited; 2003. pp 255-76.
19. Van Deventer S. Tumor necrosis factor and Crohn's disease. Gut 1997;40:443-8.
20. MacDonald T, Monteleone G, Pender S. Recent developments in the immunology of inflammatory bowel disease. Scand J Immunol 2000;51:2-9.
21. Fiocchi C. Inflammatory bowel disease; etiology and pathogenesis. Gastroenterology 1998;115:182-205.
22. Kashiwagi N, Hirata I, Kasukawa R. A role for granulocyte and monocyte apheresis in the treatment of rheumatoid arthritis. Ther Apheres 1998;2:134-41.
23. Ohara M, Saniabadi A, Kokuma S, Hirata I, Adachi M, Agishi T, et al. Granulocyte apheresis in the treatment of patients with rheumatoid arthritis. Artif Organs 1997;21: 989-94.
24. Shimoyama T, Sawada K, Tanaka T, Saito Y, Munakata A, Toyota T, et al. Granulocyte and monocyte apheresis in patients with active ulcerative colitis. Jap J Apheres 1999.
25. Saniabadi A, Hanai H, Takeuchi K, Umemura K, Nakashima M, Adachi T, et al. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apheres Dialys 2003;7:48-59.
26. Suzuki Y, Yoshimura N, Saniabadi A, Saito Y. Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naïve patients with active ulcerative colitis; a prospective uncontrolled study. Dig Dis Sci 2004; 49:565-71.
27. Hanai H, Wantanabe F, Takeuchi K, Iida T, Yamada M, Iwoka Y, et al. Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis; a prospective, uncontrolled, pilot study. Clin Gastroenterol Hepatol 2003;1: 28-35.
28. Matsui T, Nishimura T, Matake H, Ohta T, Sakurai T, Yao T. Granulocyte apheresis for Crohn's disease; a report on seven refractory patients. Am J Gastroenterol 2003;98: 511-2.
29. Ohmori T, Yamagiwa A, Nakamura I, Nishikawa K, Saniabadi A. Treatment of pyoderma gangrenosum associated with Crohn's disease. Am J Gastroenterol 2003;98: 2101-2.
30. Kanke K, Nakano M, Hiraishi H, Terano A. Clinical evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig Liver Dis 2004;36:811-7.
31. Dujorne C, Azarnoff D. Clinical complications of corticosteroid therapy. Med Clin North Am 1973;57:1331-42.
32. Margolin M, Krumholz M, Fochios S, Korelitz B. Clinical trials in ulcerative colitis; II. Historical review. Am J Gastroenterol 1988;83:227-43.
33. Truelove S, Witts L. Cortisone and corticotropin in ulcerative colitis. Br Med J 1959;1:387-94.
34. Solem C, Loftus E, Tremaine W, Sandborn W. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol 2004;99:97-101.
35. Naganuma M, Funakoshi S, Sakuraba A, Takagi H, Inoue N, Ogata H, et al. Granulocyte apheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm Bowel Dis 2004;10: 251-7.
36. Rubin D, Hanauer S. Smoking and inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000;12:855-62.